MGMT and central nervous system cancer: For molecular profiling, it reached accuracies/AUCs of 0.898/0.916 for 1p/19q codeletion, 0.829/0.896 for <i>IDH</i> mutation status, and 0.905/0.859 for <i>MGMT</i> promoter methylation, indicating strong potential utility in clinical decision support.<h4>Conclusion</h4>UMBIF showed robust transferability to both post-therapy imaging assessment and molecular status prediction in glioma.